Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas

European Journal of Cancer

Volumn 39, Issue 13, 2003, Pages 1861-1865

  Spatz, A ^a   Cook, M G ^b   Elder, D E ^c   Piepkorn, M ^d   Ruiter, D J ^e   Barnhill, R L ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Kappa statistics; Melanoma; Pathology; Reproducibility; Ulceration

Indexed keywords

ACCURACY; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DEVICE; EVALUATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; OBSERVER VARIATION; PRIORITY JOURNAL; REPRODUCIBILITY; ULCER; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; SKIN ULCER;

BIOPSY; HUMANS; MELANOMA; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SKIN ULCER;

EID: 0142058245     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00325-3     Document Type: Article

References (29)

1. Allen A.C., Spitz S. Malignant melanoma. A clinico-pathological analysis of the criteria for diagnosis and prognosis. Cancer. 6:1953;1-45.
2. Thompkins V.N. Cutaneous melanoma. ulceration as a prognostic sign Cancer. 6:1953;1215-1218.
3. Balch C.M., Wilkerson J.A., Murad T.M., Soong S.J., Ingalls A.L., Maddox W.A. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 45:1980;3012-3017.
4. Day C.L. Jr., Lew R.A., Harrist T.J. Malignant melanoma prognostic factors 4. ulceration width J. Dermatol. Surg. Oncol. 10:1984;23-24.
5. Hanekom G.S., Stubbings H.M., Johnson C.A., Kidson S.H. The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res. 9:1999;465-473.
6. Larsen T.E., Grude T.H. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 4. The relation of cross-sectional profile, level of invasion, ulceration and vascular invasion to tumour type and prognosis. Acta Pathol. Microbiol. Scand. [A]. 87A:1979;131-138.
7. McGovern V.J., Shaw H.M., Milton G.W., McCarthy W.H. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology. 6:1982;399-407.
8. Weidner F., Schroll S., Schonberger A. The influence of lymph node metastasis and ulceration of primary melanoma on germinal centers within draining lymph nodes. a histomorphometric study Arch. Dermatol. Res. 272:1982;155-161.
9. Balch C.M., Buzaid A.C., Soong S.J.et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19:2001;3635-3648.
10. Balch C.M., Soong S.J., Gershenwald J.E.et al. Prognostic factors analysis of 17,600 melanoma patients. validation of the American Joint Committee on Cancer melanoma staging system J. Clin. Oncol. 19:2001;3622-3634.
11. Corona R., Mele A., Amini M.et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J. Clin. Oncol. 14:1996;1218-1223.
12. Lock-Andersen J., Hou-Jensen K., Hansen J.P., Jensen N.K., Sogaard H., Andersen P.K. Observer variation in histological classification of cutaneous malignant melanoma. Scand. J. Plast. Reconstr. Surg. Hand Surg. 29:1995;141-148.
13. Heenan P.J., Matz L.R., Blackwell J.B.et al. Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia. Histopathology. 8:1984;717-729.
14. Ruiter D.J., Spatz A., van den Oord J.J., Cook M.G. Pathologic staging of melanoma. Semin. Oncol. 29:2002;370-381.
15. Ruiter D.J., Spatz A., van den Oord J.J., Cook M.G. Microstaging in cutaneous melanoma. J. Pathol. 195:2001;525-529.
16. Cohen A. Comparison of correlated correlations. Stat. Med. 8:1989;1485-1495.
17. Hoang M.P., Sahin A.A., Ordonez N.G., Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am. J. Clin. Pathol. 113:2000;852-859.
18. Thompson J.R. Estimating equations for kappa statistics. Stat. Med. 20:2001;2895-2906.
19. Tubbs R., Skacel M., Pettay J.et al. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am. J. Surg. Pathol. 26:2002;908-913.
20. Eggermont A.M., Keilholz U., Autier P., Ruiter D.J., Lehmann F., Lienard D. The EORTC Melanoma Group. a comprehensive melanoma research programme by clinicians and scientists. European Organization for Research and Treatment of Cancer Eur. J. Cancer. 38(Suppl. 4):2002;S114-S119.
21. Cochran A.J., Elashoff D., Morton D.L., Elashoff R. Individualized prognosis for melanoma patients. Hum. Pathol. 31:2000;327-331.
22. Lang P.G. Current concepts in the management of patients with melanoma. Am. J. Clin. Dermatol. 3:2002;401-426.
23. Bartoli C., Bono A. Comments on Management of cutaneous melanoma M0. state of the art and trends, Rossi et al. Eur J Cancer, 1997, 33, 2302-2312 Eur. J. Cancer. 34:1998;1467-1468.
24. Eggermont A.M. Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eur. J. Cancer. 34(Suppl. 3):1998;S22-S26.
25. Eggermont A.M. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma. prognosis versus efficacy, toxicity and costs Melanoma Res. 7(Suppl. 2):1997;S127-S131.
26. Buzaid A.C., Anderson C.M. The changing prognosis of melanoma. Curr. Oncol. Rep. 2:2000;322-328.
27. Cascinelli N., Marubini E., Morabito A., Bufalino R. Prognostic factors for stage I melanoma of the skin. a review Stat. Med. 4:1985;265-278.
28. Cherpelis B.S., Haddad F., Messina J.et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J. Am. Acad. Dermatol. 44:2001;762-766.
29. Busam K.J. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. Am. J. Clin. Pathol. 115:2001;743-746.